- Tytuł:
- Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.
- Autorzy:
- Źródło:
- Neurology & Therapy. Jun2017, Vol. 6 Issue 1, p153-159. 7p.
Czasopismo naukowe